Botswana Smoking Abstinence Reinforcement Trial (BSMART)

博茨瓦纳戒烟强化试验（BSMART）

• 批准号: 10541071
• 负责人: Manhattan E Charurat
• 金额: $ 75.47万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10541071
• 关键词: AIDS/HIV problem; Abstinence; Address; Adoption; Africa South of the Sahara; Assessment tool; Baltimore; Biochemical; Botswana; Cancer Burden; Cancer Control; Caring; Case Manager; Centers for Disease Control and Prevention (U.S.); Clinic; Clinical effectiveness; Control Groups; Demographic and Health Surveys; Development; Effectiveness; Evidence based intervention; Formularies; Fostering; Government; HIV; HIV Infections; Health; Health care facility; Health system; Information Systems; Infrastructure; Intervention; Malignant Neoplasms; Malignant neoplasm of lung; Maryland; Monitor; Nurses; Outpatients; Participant; Persons; Pharmaceutical Preparations; Policies; Premature Mortality; Prevalence; Prevention strategy; Program Sustainability; Psychological reinforcement; Reach Effectiveness Adoption Implementation and Maintenance; Recommendation; Research Design; Sample Size; Smoking Cessation Intervention; Southern Africa; Structure; Time; Tobacco; Tobacco use; Training; United States National Institutes of Health; Universities; Work; base; cancer prevention; care systems; clinical research site; combustible tobacco; comorbidity; cost effectiveness; design; effectiveness evaluation; effectiveness implementation study; evidence base; follow-up; implementation fidelity; implementation science; implementation strategy; indexing; intervention delivery; intervention program; low and middle-income countries; population health; programs; routine practice; screening, brief intervention, referral, and treatment; smoking abstinence; smoking cessation; smoking prevalence; standard of care; syndemic; tobacco products; trial comparing; varenicline

PROJECT ABSTRACT Tobacco use is highly prevalent among people living with HIV/AIDS (PLWH) especially in southern Africa where HIV is most heavily concentrated. Among PLWH, tobacco use impacts HIV-related co-morbidities and is the leading cause of premature mortality from non-HIV related malignancies such as lung cancer which account for 20% of the cancer burden. Integrating an evidence-based intervention, such as Screening, Brief Intervention and Referral to Treatment (SBIRT) into a HIV care system presents an important opportunity to establish and evaluate a modifiable cancer prevention strategy into a low- and middle-income country (LMIC) setting where both lay health workers (LHW) and non-physician clinicians are widely used. Botswana, where the University of Maryland Baltimore (UMB) has worked since 2015, oversees a wide network of HIV care clinics for its citizens. Demographic Health Surveys from sub-Saharan Africa show that smoking prevalence among PLWH ranges 12.5-44.3%. Yet, based on our pilot data the system of care is highly unprepared to meet the challenge of integrating evidence-based smoking cessation treatment into routine HIV care. The Government of Botswana wants more to be done to assist its citizen in smoking cessation. To meet this challenge, the Botswana Smoking Abstinence Reinforcement Trial (BSMART) proposes to use a Type 2 hybrid effectiveness-implementation study design to evaluate the effectiveness and implementation of a well-established SBIRT intervention consisting of the 5As, (Ask, Advise, Assess, Assist, Arrange) delivered by trained LHW case managers, followed by referral to treatment with varenicline (a medication demonstrated to be efficacious for smoking cessation among PLWH1-3 and on formulary in Botswana) prescribed and monitored by trained nurse prescribers-dispensers, in the network of outpatient HIV care facilities in Botswana. The specific aims guided by the RE-AIM Framework and informed by an Implementation Governance Structure are to: 1) Assess Reach and Effectiveness of BSMART; 2) Assess the Adoption and Implementation indexed by quality and consistency of intervention delivery; 3) Assess whether the intervention becomes Maintained as part of routine practices; 4) Determine the preliminary cost-effectiveness of BSMART.

项目摘要 烟草使用在艾滋病毒/艾滋病患者中非常普遍，特别是在南部非洲 艾滋病毒最为集中。在PLWH中，烟草使用影响艾滋病毒相关的共病，是 肺癌等非艾滋病毒相关恶性肿瘤过早死亡的主要原因 20%的癌症负担。整合循证干预措施，如筛查、短暂干预和 转诊治疗(SBIRT)进入艾滋病毒护理系统提供了一个重要机会，以建立和 在低收入和中等收入国家(LMIC)环境中评估可修改的癌症预防战略 非内科医务人员和非内科临床医生都被广泛使用。博茨瓦纳，那里的大学 马里兰州巴尔的摩(UMB)自2015年以来一直在工作，为其公民监督广泛的艾滋病毒护理诊所网络。 来自撒哈拉以南非洲的人口健康调查显示，在PLWH范围内的吸烟流行率 12.5-44.3%。然而，根据我们的试点数据，医疗保健系统对迎接 将循证戒烟治疗纳入常规艾滋病毒护理。博茨瓦纳政府 希望做更多的工作来帮助其公民戒烟。为了迎接这一挑战，博茨瓦纳吸烟者 戒断强化试验(BSMART)建议使用类型2混合有效性-实施研究 设计评估良好的SBIRT干预措施的有效性和实施情况，包括 由训练有素的LHW案例经理提供的5A(询问、建议、评估、协助、安排)，然后转介 使用varenicline(一种被证明对戒烟有效的药物)治疗 PLWH1-3和博茨瓦纳的处方)，由训练有素的护士处方师-配药员处方和监测) 博茨瓦纳的艾滋病毒门诊护理设施网络。RE-AIM框架指导下的具体目标 并由执行治理结构提供信息：1)评估覆盖范围和有效性 BSMART；2)通过干预措施的质量和一致性来评估采用和实施情况 交付；3)评估干预是否成为常规做法的一部分；4)确定 BSMART的初步成本-效果分析。